How Intas Pharmaceuticals’ Expansion Plans Could Affect Its Share Price in the Coming Years

Intas Pharmaceuticals is a notable and phenomenal player in the global international and domestic pharmaceutical marketplace that experts in developing, manufacturing, and advertising a wide variety of drugs and medications throughout various therapeutic regions. The company has drawn enormous attention and interest because of its bold growth plans, which include bolstering manufacturing and research capacities.

Understanding how these strategies might impact Intas Pharmaceuticals share price is essential for those thinking about investments in the healthcare region. This article dives into Intas’ growth strategies and what they could mean for its share performance in the future, particularly in light of the anticipation around its potential public listing.

About Intas Pharmaceuticals

Intas Pharmaceuticals, headquartered in Ahmedabad, India has expanded its feet to become one of India's largest pharmaceutical companies and top in terms of oncology medication facilities, with an extensive and comprehensive portfolio that spans both generic and specialty medications and drugs. The company is well known for its strong presence within the domestic market. Intas has also made a name and positioned itself internationally, especially within the United States and Europe, wherein its generics business is thriving. 

The company, recognized for its various and diverse products and extensive R&D projects initiatives, has drawn attention and sufficient interest from retail and institutional investors, with curiosity surging regarding its potential IPO and the pricing of Intas Pharma unlisted shares.

Expansion Goals: Manufacturing Facility

Intas Pharmaceuticals Limited is the sixth-biggest domestic formulation organization in India as of March 2024. The domestic market contributes significantly to the company’s overall revenue, accounting for around 39% of its total turnover for FY24.

Intas operates 14 commercial manufacturing facilities in India,  assisting a range of therapeutic categories.  In addition to its India-primarily based operations, Intas has also invested in worldwide manufacturing and production capabilities. 

Intas Pharmaceuticals plans to utilize the funds from the Intas Pharma IPO to make effective utilization and to expand its production and R&D capabilities. The organization has allocated Rs. 218 Crs. from its proposed public offering for these expansion goals which include modernizing and upgrading contemporary facilities,  setting up new offices in Ahmedabad and Mumbai, and improving R&D centres. Additionally, Rs. 45.7 Crs. has been allocated for the Matoda facility to enhance production manufacturing and increase specialized veterinary medicine lines and Rs. 5.2 Crs. allotted for the Valia facility where it manufactures active pharmaceutical ingredients (API).

This investment supports and aligns with Intas' strategic purpose of creating innovative, cost-effective medications and drugs. Such a focus on R&D can enhance Intas Pharmaceuticals' share price as innovative, groundbreaking products give a boost to the company’s competitive edge. 

Intas Pharmaceuticals’ Expansion Strategy

Intas has pursued increases through both natural and inorganic strategies and methods. Its focus on R&D, international market expansion, and strategic acquisitions has allowed the company to expand its footprint and make a global presence, and diversify its services. In recent years, Intas obtained the United Kingdom and Irish assets of Actavis from Teva Pharmaceuticals, broadening its reach across Europe. The company’s ability to merge acquired businesses and leverage existing synergies has positioned it as a sturdy and robust contender competitor on the global stage.

In terms of product cognizance, Intas has targeted rapidly expanding growth in therapeutic areas such as oncology, neurology, and cardiovascular treatments. These segments offer significant growth potential, especially in markets just like the U.S. And Europe.

Strengthening Global Footprint and Market Share

International markets play a critical role in Intas’s revenue stream. Around more than 50% of its revenue earnings are derived from global international sales, the company’s expansion method prioritizes securing registrations for new products, especially in Europe. Intas has earmarked and allocated Rs. 108.5 crores. for worldwide product registrations, aiming to release 71 new products across European markets. This method aligns with Intas’ broader imagination and prescient of world growth, doubtlessly driving growth in Intas pharma share price target 2025 as new sales and revenue streams from these markets emerge.

Intas Pharmaceuticals Share Price

Intas’s current ownership structure and strategic partnerships enhance and bolster its potential for growth. Notable prominent investors like Temasek Holdings preserve and maintain a 10.16% stake, received through a Rs. 880 crore transaction with ChrysCapital. 

The face value of Intas Pharmaceuticals share is ₹10 per share along with the Intas share price in the unlisted market at approximately ₹5,800 per share. This price reflects the company’s growth opportunities, supported and backed by expansion plans and strategies focused on both production manufacturing and research centers. The IPO aims to raise approximately ₹425 crore, primarily to fund these activities.

Financial Performance and Future Outlook

Intas continues to set incredible financial benchmarks with a compound annual growth rate of 28% over the last 5 years. The company recently announced revenues surpassing ₹18,351 crore in FY22 to ₹20,086 crore in FY23, attaining an 8.25% growth rate, underscoring its profitability and operational efficiency and then the revenue in FY24 to ₹19,667 (marginal decline due to volatility in the US market). Strong financials and a steady international footprint make Intas Pharma unlisted shares a compelling preference for pre-IPO investors.  

Intas Pharmaceuticals operates in India’s domestic market and some of the most highly regulated pharmaceutical markets, consisting of the US, the United Kingdom, and Europe. In FY23, it carried out consolidated revenue across these diverse regions, highlighting its vast worldwide global presence.

Intas Pharmaceuticals’ Competitors and Market Positioning

Intas operates in a competitive market space, contending with other Indian pharmaceutical giants like Sun Pharmaceuticals, Cipla, and Lupin. Each company is running and striving to increase its share of the global generics market. What differentiates Intas is its strategic acquisitions and its sustained focus on Europe, which is an exceptionally lucrative market for generics.

​

Anticipated Market Impact and Investor Sentiment

The Intas Pharma IPO provides an opportunity for both new and current existing investors to gain exposure to a thriving pharmaceutical player with huge extensive global and  international reach. The  Intas Pharma IPO creates market buzz and highlights Intas' attractiveness, backed by its strong financials and promising expansion initiatives. For investors targeted on sustainable, long-term returns, Intas pharma share price offers substantial potential.

Intas Pharma plans to dilute 10% of its stake through its upcoming IPO, with private equity investor ChrysCapital also decreasing and reducing its stake by about approximately 5%. Following the Intas Pharma IPO, public shareholders will keep a 15% stake ownership in the company. The promoters are anticipated to retain an 80% stake, even as ChrysCapital will keep a 5% share portion. Intas anticipates to conclude the year with a turnover surpassing ₹1,800 crore, reinforcing its financial strength as it steps into the public market.

Conclusion

Intas Pharmaceuticals’ expansion plans and consistent financial overall performance set the stage for an impactful increase within the pharmaceutical sector. From enhancing manufacturing abilities to diversifying R&D projects, these strategic movements give Intas valuable attention in each of the unlisted and public markets. As with the Intas Pharma IPO tactics, the company's increased strategies and market capabilities enhance its appeal to investors looking for exciting opportunities in the pharmaceutical sector.

​